Menu Search
Equities

Prim SA

5P1:FRA

Prim SA

Actions
Health CareMedical Equipment and Services
  • Price (EUR)9.50
  • Today's Change0.02 / 0.21%
  • Shares traded149.00
  • 1 Year change-12.84%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 19:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Prim SA is a Spain-based company principally engaged in the provision of hospital supplies. The Company’s products portfolio comprises implantable orthopedic products, silicone foot products, abduction splints, mastectomy lingerie, prosthetic components, as well as articulated electric beds and various types of accessories for geriatric centers. Through its subsidiary Inmobiliaria Catharsis SA, the Company is also active in the Real State sector. Prim SA is a parent of Grupo Prim, a group which comprises such a number of controlled entities as Enraf Nonius Iberica SA, Establecimientos Ortopedicos Prim SA, and Luga Suministros Medicos SL, among others.

  • Revenue in EUR (TTM)227.46m
  • Net income in EUR11.43m
  • Incorporated--
  • Employees901.00
  • Location
    Prim SACalle Fnumero 15., Polig. Industrial numero 1MOSTOLES 28938SpainESP
  • Phone+34 913342400
  • Fax+34 913342494
  • Websitehttps://www.prim.es/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.